Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Common-Size Income Statement
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Gilead Sciences Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Product sales
Cost of goods sold
Gross profit on product sales
Royalty, contract and other revenues
Research and development expenses
Acquired in-process research and development expenses
In-process research and development impairments
Selling, general and administrative expenses
Operating income (loss)
Interest expense
Other income (expense), net
Income (loss) before income taxes
Income tax (expense) benefit
Net income (loss)
Net loss attributable to noncontrolling interest
Net income (loss) attributable to Gilead

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The financial data presents multiple quarters of performance measured as percentages of product sales. Observations across key financial metrics reveal varying trends and fluctuations over the reported periods.

Gross Profit on Product Sales
Gross profit consistently remains the majority portion relative to product sales, typically ranging from approximately 63% to 83%. Notably, there is a pronounced dip to 63.31% in Dec 2021, followed by a recovery to levels near or above 76% in subsequent quarters. This suggests periods of increased cost pressures or other factors impacting gross margins transiently yet stabilizing afterward.
Cost of Goods Sold (COGS)
The cost of goods sold exhibits considerable variability, fluctuating between roughly -16.6% and a higher negative peak of -36.69% of product sales. The spike in COGS in Dec 2021 aligns with the significant dip in gross profit observed during the same quarter, implying an extraordinary increase in costs during this period before normalizing.
Research and Development Expenses (R&D)
R&D expenses as a percentage of product sales display a moderately wide range, from about -15.6% to nearly -29%. There are instances of elevated R&D spending in certain quarters, such as Dec 2021 and Dec 2022, indicating periodic intensification of investment in development activities. Despite fluctuations, the general level of R&D appears stable with periodic peaks.
Acquired In-Process Research and Development Expenses (IPR&D)
IPR&D expenses are more sporadic and volatile, with some quarters showing significant negative percentages (e.g., -89.28% in Jun 2020, -62.15% in Mar 2024). Several quarters lack data, indicating either no acquisition activity or unreported figures. The extreme variability suggests episodic acquisitions or impairments related to in-process R&D.
In-Process R&D Impairments
Reported impairments appear irregular but substantial when present. For example, a large impairment of -41.32% occurs in Sep 2022. These indicate occasional write-downs of acquired or in-progress R&D projects affecting profitability disproportionately in certain quarters.
Selling, General and Administrative Expenses (SG&A)
SG&A expenses hover mostly between approximately -16.5% and -28% of product sales. The spikes align with several quarters such as Dec 2022 where elevated administrative or selling costs were incurred. Overall, SG&A costs maintain a consistent portion of sales with some variability.
Operating Income (Loss)
Operating income displays broad fluctuations, with some quarters experiencing robust positive returns above 40% (e.g., Mar 2020 and Sep 2021) and others showing sharp declines or losses (e.g., Jun 2020 at -58.87% and Mar 2024 at -65.02%). Such swings imply sensitivity of operational profitability to underlying cost structures and expense volatility.
Interest Expense
Interest expenses remain relatively stable, fluctuating moderately around -3% to -4.7% of product sales. This indicates consistent financing costs relative to the revenue base over time.
Net Income (Loss) and Attributable Net Income
Net income mirrors the pattern of operating income with notable volatility. The presence of several quarters with significant losses (e.g., -66.04% in Jun 2020 and -62.74% in Mar 2024) contrasts with quarters of strong positive net income exceeding 28%. Net income attributable to the company closely tracks total net income, reflecting limited impact from noncontrolling interests.
Income Tax Expense
Income tax expense fluctuates between negative and positive figures, with some quarters showing tax benefits (e.g., positive values in Mar 2022 and Jun 2024). This variability may arise from changing profitability and tax planning effects across periods.

Overall, the data reveals a pattern of volatility particularly in costs related to goods sold, R&D, and impairments which significantly influence profitability measures. While product sales remain steady as a reference base, fluctuations in expenses and impairments result in pronounced earnings variability. Stability in interest expenses contrasts with the episodic nature of acquisition-related costs and impairments. The trends suggest periods of reinvestment and restructuring impact operating results intermittently, with eventual restoration to more normalized profitability levels.